期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.663201
关键词
chimeric antigen receptor T cell; immunotherapy; adverse reactions; mechanism; coping strategies
类别
资金
- Special Research Project of Lanzhou University Serving the Economic and Social Development of Gansu Province [054000282]
- Lanzhou Talent Innovation and Entrepreneurship Project [2020-RC-38]
- Fundamental Research Funds for the Central Universities [lzujbky-2020-kb14]
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in tumor immunotherapy, but it is also associated with serious adverse reactions. Early identification and effective treatment of these adverse reactions are crucial in order to ensure the safe and successful clinical application of CAR-T cell therapy.
The application of chimeric antigen receptor (CAR) T-cell therapy as a tumor immunotherapy has received great interest in recent years. This therapeutic approach has been used to treat hematological malignancies solid tumors. However, it is associated with adverse reactions such as, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), off-target effects, anaphylaxis, infections associated with CAR-T-cell infusion (CTI), tumor lysis syndrome (TLS), B-cell dysplasia, hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) and coagulation disorders. These adverse reactions can be life-threatening, and thus they should be identified early and treated effectively. In this paper, we review the adverse reactions associated with CAR-T cells, the mechanisms driving such adverse reactions, and strategies to subvert them. This review will provide important reference data to guide clinical application of CAR-T cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据